Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Primary Myelofibrosis 16Polycythemia Vera 14Myeloproliferative Disorders 11Leukemia, Myeloid, Acute 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Myelodysplastic Syndromes 5Hematologic Diseases 5Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Graft vs Host Disease 4Bone Marrow Diseases 4Thrombocythemia, Essential 3Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Thrombocytosis 2Pancreatic Neoplasms 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Bronchiolitis Obliterans Syndrome 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Preleukemia 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × ruxolitinib × Clear all
NCT03012230 2024-01-31

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

Mayo Clinic

Phase 1 Completed
12 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡